Magnetic Resonance Spectroscopy Findings and Cognitive Function in Patients with Parkinson’s disease

Background and Purpose: Cognitive impairment (CI) is one of the most notable disabilities of Parkinson’s disease that is associated with lower quality of life. Early detection of CI is therefore very important for these patients. The purpose of this study was to examine the relationship between cogn...

Full description

Bibliographic Details
Main Authors: Farzad Ashrafi, Abdolnasser Rostami, Mehran Arab Ahmadi, Behdad Behnam
Format: Article
Language:English
Published: Shahid Beheshti University of Medical Sciences 2017-04-01
Series:International Clinical Neuroscience Journal
Online Access:http://journals.sbmu.ac.ir/Neuroscience/article/download/16997/3
_version_ 1811224811991465984
author Farzad Ashrafi
Abdolnasser Rostami
Mehran Arab Ahmadi
Behdad Behnam
author_facet Farzad Ashrafi
Abdolnasser Rostami
Mehran Arab Ahmadi
Behdad Behnam
author_sort Farzad Ashrafi
collection DOAJ
description Background and Purpose: Cognitive impairment (CI) is one of the most notable disabilities of Parkinson’s disease that is associated with lower quality of life. Early detection of CI is therefore very important for these patients. The purpose of this study was to examine the relationship between cognitive function and the metabolic data from magnetic resonance spectroscopy (MRS) of the patient suffering with Parkinson’s disease. Methods: Totally, 45 patients with Parkinson’s disease were used in this study. Subjects were divided into three groups based on scales for outcome from Parkinson cognition (SCOPACOG) test. Patients were classified as non-cognitive impairment (NCI; n=15), mild cognitive impairment (MCI; n=15) and dementia (PDD; n=15). All subjects underwent MRI and 1 H-MRS techniques and metabolic changes such as NAA/Cr and NAA/Cho ratios, which were measured in the left hippocampal area of the brain. Results: The mean and standard deviation of the NAA/Cr ratio in the three cognitive groups (NCI, MCI, PDD) were (2.51±0.037), (2.50±0.033) and (2.47±0.025), respectively. ANOVA test showed a significant difference in the three groups. Furthermore, the Scheffé test showed a significant difference between patients in the MCI and PDD groups (p=0.01). There was no significant difference between the non-cognitive impairment and mild cognitive impairment groups (p=0.54). No significant difference was found in NAA/Cho ratio (p=091). Conclusion: A decreasing NAA/Cr ratio has influence on cognitive function and the development of severe cognitive dysfunction in Parkinson suffering patients. Furthermore, 1 H-MRS determinant can be useful to evaluate cognition in Parkinson patients.
first_indexed 2024-04-12T08:55:23Z
format Article
id doaj.art-cd4239dae3ef47e4a25c9707001a7cd8
institution Directory Open Access Journal
issn 2383-1871
2383-2096
language English
last_indexed 2024-04-12T08:55:23Z
publishDate 2017-04-01
publisher Shahid Beheshti University of Medical Sciences
record_format Article
series International Clinical Neuroscience Journal
spelling doaj.art-cd4239dae3ef47e4a25c9707001a7cd82022-12-22T03:39:26ZengShahid Beheshti University of Medical SciencesInternational Clinical Neuroscience Journal2383-18712383-20962017-04-0142465010.22037/icnj.v4i2.16997icnj-3121Magnetic Resonance Spectroscopy Findings and Cognitive Function in Patients with Parkinson’s diseaseFarzad Ashrafi0Abdolnasser Rostami1Mehran Arab Ahmadi2Behdad Behnam3Functional Neurosurgery Research Center, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Department of Radiology School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IranFunctional Neurosurgery Research Center, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Functional Neurosurgery Research Center, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Background and Purpose: Cognitive impairment (CI) is one of the most notable disabilities of Parkinson’s disease that is associated with lower quality of life. Early detection of CI is therefore very important for these patients. The purpose of this study was to examine the relationship between cognitive function and the metabolic data from magnetic resonance spectroscopy (MRS) of the patient suffering with Parkinson’s disease. Methods: Totally, 45 patients with Parkinson’s disease were used in this study. Subjects were divided into three groups based on scales for outcome from Parkinson cognition (SCOPACOG) test. Patients were classified as non-cognitive impairment (NCI; n=15), mild cognitive impairment (MCI; n=15) and dementia (PDD; n=15). All subjects underwent MRI and 1 H-MRS techniques and metabolic changes such as NAA/Cr and NAA/Cho ratios, which were measured in the left hippocampal area of the brain. Results: The mean and standard deviation of the NAA/Cr ratio in the three cognitive groups (NCI, MCI, PDD) were (2.51±0.037), (2.50±0.033) and (2.47±0.025), respectively. ANOVA test showed a significant difference in the three groups. Furthermore, the Scheffé test showed a significant difference between patients in the MCI and PDD groups (p=0.01). There was no significant difference between the non-cognitive impairment and mild cognitive impairment groups (p=0.54). No significant difference was found in NAA/Cho ratio (p=091). Conclusion: A decreasing NAA/Cr ratio has influence on cognitive function and the development of severe cognitive dysfunction in Parkinson suffering patients. Furthermore, 1 H-MRS determinant can be useful to evaluate cognition in Parkinson patients.http://journals.sbmu.ac.ir/Neuroscience/article/download/16997/3
spellingShingle Farzad Ashrafi
Abdolnasser Rostami
Mehran Arab Ahmadi
Behdad Behnam
Magnetic Resonance Spectroscopy Findings and Cognitive Function in Patients with Parkinson’s disease
International Clinical Neuroscience Journal
title Magnetic Resonance Spectroscopy Findings and Cognitive Function in Patients with Parkinson’s disease
title_full Magnetic Resonance Spectroscopy Findings and Cognitive Function in Patients with Parkinson’s disease
title_fullStr Magnetic Resonance Spectroscopy Findings and Cognitive Function in Patients with Parkinson’s disease
title_full_unstemmed Magnetic Resonance Spectroscopy Findings and Cognitive Function in Patients with Parkinson’s disease
title_short Magnetic Resonance Spectroscopy Findings and Cognitive Function in Patients with Parkinson’s disease
title_sort magnetic resonance spectroscopy findings and cognitive function in patients with parkinson s disease
url http://journals.sbmu.ac.ir/Neuroscience/article/download/16997/3
work_keys_str_mv AT farzadashrafi magneticresonancespectroscopyfindingsandcognitivefunctioninpatientswithparkinsonsdisease
AT abdolnasserrostami magneticresonancespectroscopyfindingsandcognitivefunctioninpatientswithparkinsonsdisease
AT mehranarabahmadi magneticresonancespectroscopyfindingsandcognitivefunctioninpatientswithparkinsonsdisease
AT behdadbehnam magneticresonancespectroscopyfindingsandcognitivefunctioninpatientswithparkinsonsdisease